

NEWS DIGEST

- Exploration of Artificial intelligence in medicine development
- Deep dive into what real-world evidence actually is
- 3 things to know about England's new integrated care systems
- What will be the blockbuster drugs in the next decade?



ARTIFICIAL INTELLIGENCE IN MEDICINE DEVELOPMENT

THE NEWS

The global artificial intelligence (AI) in healthcare market is expected to reach USD 61.59 billion by 2027.

Pharma adoption of AI is making an important contribution to this rise. AI's usage in the pharmaceutical business is growing in multiple ways including medication discovery and development.

IN OUR ARTICLE

We share the three top areas where AI workflows are being applied in medicine development.

Source: <https://bit.ly/3hr5PoP>



REAL WORLD EVIDENCE EXPLAINED

THE NEWS

Real-world evidence (RWE) refers to clinical and economic evidence which has been derived from the analysis of real-world data (RWD).

RWE is important way to enable manufacturers to gain an understanding of a drug's safety and effectiveness when taken by patients in uncontrolled settings, that are more reflective of real-world practice.

This can be beneficial in demonstrating the value of a product to regulators, payers, and health care professionals.

Unlike traditional randomised controlled trials (RCTs)

IN OUR ARTICLE

We explore the types of real-world evidence studies conducted and the advantages and limitations of real-world evidence.

Source: <https://bit.ly/3lrJn05>



ENGLAND'S NEW INTEGRATED CARE SYSTEM

THE NEWS


Integrated Care Systems (ICS) have been designed to enable health and care organisations to join forces in improving resident health, tackling variation in care, preventing illnesses and ensuring that each pound is maximised.

IN OUR ARTICLE

We provide a little more detail on how ICSs will be integrated into the NHS and the key things you need to know.

Through adaptive algorithms patients receive personalised treatments that encourage them to continuously improve their performance and allow their progress to be tracked in real time.

source: <https://bit.ly/3nqYXeW>



BLOCKBUSTER DRUGS OF THE NEXT DECADE

THE NEWS

Which treatments have been recently approved by the regulators in the US and EU?

Until June 30th, 2021, the Food and Drug Administration (FDA) in the US and European Medicine Agency in Europe have launched 32 and 22 new drugs, respectively.

This represents a notable increase in the number of approved molecules by the two regulators during the first half of 2020.

IN OUR ARTICLE

We provide detail on the eight most promising recently approved treatments by the FDA or European Medicine Agency (EMA) measured by their sales forecast.

source: <https://bit.ly/3z47W80>



GET IN TOUCH

"We always welcome your thoughts and opinions on the topics raised here.

If you'd like to share anything or hear how we can support you in getting your product to market email Paul and Graham, managing directors, today at:
contact@remapconsulting.com"



Paul Craddy
Managing Director & Founder



Graham Foxon
Managing Director & Founder

